• Something wrong with this record ?

Renal Sympathetic Denervation as Upstream Therapy During Atrial Fibrillation Ablation: Pilot HFIB Studies and Meta-Analysis

MK. Turagam, W. Whang, MA. Miller, P. Neuzil, A. Aryana, A. Romanov, FA. Cuoco, M. Mansour, D. Lakkireddy, GF. Michaud, SR. Dukkipati, S. Cammack, VY. Reddy

. 2021 ; 7 (1) : 109-123. [pub] 20201028

Language English Country United States

Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026275

OBJECTIVES: This study sought to determine the impact of adjunctive renal sympathetic denervation to catheter ablation in patients with atrial fibrillation (AF) and history of hypertension. BACKGROUND: There are limited data regarding the impact of upstream adjunctive renal sympathetic denervation (RSDN) to pulmonary vein isolation (PVI) in patients with symptomatic atrial fibrillation (AF) and hypertension. METHODS: The data for this study were obtained from 2 prospective randomized pilot studies, the HFIB (Adjunctive Renal Denervation to Modify Hypertension and Sympathetic tone as Upstream Therapy in the Treatment of Atrial Fibrillation)-1 (n = 30) and HFIB (Adjunctive Renal Denervation to Modify Hypertension and Sympathetic tone as Upstream Therapy in the Treatment of Atrial Fibrillation)-2 (n = 50) studies, and we performed a meta-analysis including all published studies comparing RSDN+PVI versus PVI alone up to January 25, 2020, in patients with AF and hypertension. RESULTS: At 24 months, AF recurrence occurred in 53% and 38% in the PVI and PVI+RSDN groups (p = 0.43) in the HFIB-1 study, respectively, and 27% and 25% in the PVI and PVI+RSDN groups (p = 0.80) in the HFIB-2 study, respectively. When combined in a meta-analysis including 6 studies (n = 725), adjunctive RSDN significantly decreased the risk of AF recurrence (risk ratio [RR]: 0.68; 95% confidence interval [CI]: 0.55 to 0.83; p = 0.0002; I2 = 0%) when compared with PVI. Six renal artery complications occurred in the HFIB-1 study and none occurred in the HFIB-2 study with RSDN. However, in the meta-analysis, there were no significant differences in overall complications between both groups (RR: 1.43; 95% CI: 0.63 to 3.22; p = 0.40; I2 = 7%). When compared with baseline, RDSN significantly reduced the systolic blood pressure (-12.1 mm Hg; 95% CI: -20.9 to -3.3 mm Hg; p < 0.007; I2 = 99%) and diastolic blood pressure (-5.60 mm Hg; 95% CI: -10.05 to -1.10 mm Hg; p = 0.01; I2 = 98%) on follow-up. CONCLUSIONS: The pilot HFIB-1 and HFIB-2 studies did not demonstrate a benefit with RSDN as an adjunctive upstream therapy during PVI. However, in the meta-analysis, adjunctive RSDN to PVI appears to be safe, and improves clinical outcomes in AF patients with a history of hypertension.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026275
003      
CZ-PrNML
005      
20211026133036.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2020.08.013 $2 doi
035    __
$a (PubMed)33478702
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Turagam, Mohit K $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
245    10
$a Renal Sympathetic Denervation as Upstream Therapy During Atrial Fibrillation Ablation: Pilot HFIB Studies and Meta-Analysis / $c MK. Turagam, W. Whang, MA. Miller, P. Neuzil, A. Aryana, A. Romanov, FA. Cuoco, M. Mansour, D. Lakkireddy, GF. Michaud, SR. Dukkipati, S. Cammack, VY. Reddy
520    9_
$a OBJECTIVES: This study sought to determine the impact of adjunctive renal sympathetic denervation to catheter ablation in patients with atrial fibrillation (AF) and history of hypertension. BACKGROUND: There are limited data regarding the impact of upstream adjunctive renal sympathetic denervation (RSDN) to pulmonary vein isolation (PVI) in patients with symptomatic atrial fibrillation (AF) and hypertension. METHODS: The data for this study were obtained from 2 prospective randomized pilot studies, the HFIB (Adjunctive Renal Denervation to Modify Hypertension and Sympathetic tone as Upstream Therapy in the Treatment of Atrial Fibrillation)-1 (n = 30) and HFIB (Adjunctive Renal Denervation to Modify Hypertension and Sympathetic tone as Upstream Therapy in the Treatment of Atrial Fibrillation)-2 (n = 50) studies, and we performed a meta-analysis including all published studies comparing RSDN+PVI versus PVI alone up to January 25, 2020, in patients with AF and hypertension. RESULTS: At 24 months, AF recurrence occurred in 53% and 38% in the PVI and PVI+RSDN groups (p = 0.43) in the HFIB-1 study, respectively, and 27% and 25% in the PVI and PVI+RSDN groups (p = 0.80) in the HFIB-2 study, respectively. When combined in a meta-analysis including 6 studies (n = 725), adjunctive RSDN significantly decreased the risk of AF recurrence (risk ratio [RR]: 0.68; 95% confidence interval [CI]: 0.55 to 0.83; p = 0.0002; I2 = 0%) when compared with PVI. Six renal artery complications occurred in the HFIB-1 study and none occurred in the HFIB-2 study with RSDN. However, in the meta-analysis, there were no significant differences in overall complications between both groups (RR: 1.43; 95% CI: 0.63 to 3.22; p = 0.40; I2 = 7%). When compared with baseline, RDSN significantly reduced the systolic blood pressure (-12.1 mm Hg; 95% CI: -20.9 to -3.3 mm Hg; p < 0.007; I2 = 99%) and diastolic blood pressure (-5.60 mm Hg; 95% CI: -10.05 to -1.10 mm Hg; p = 0.01; I2 = 98%) on follow-up. CONCLUSIONS: The pilot HFIB-1 and HFIB-2 studies did not demonstrate a benefit with RSDN as an adjunctive upstream therapy during PVI. However, in the meta-analysis, adjunctive RSDN to PVI appears to be safe, and improves clinical outcomes in AF patients with a history of hypertension.
650    12
$a fibrilace síní $x chirurgie $7 D001281
650    12
$a katetrizační ablace $7 D017115
650    _2
$a lidé $7 D006801
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a recidiva $7 D012008
650    _2
$a sympatektomie $7 D013562
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Whang, William $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Miller, Marc A $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Aryana, Arash $u Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA
700    1_
$a Romanov, Alexander $u E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, Russia
700    1_
$a Cuoco, Frank A $u Trident Health System, Charleston, South Carolina, USA
700    1_
$a Mansour, Moussa $u Massachusetts General Hospital, Boston, Massachusetts, USA
700    1_
$a Lakkireddy, Dhanunjaya $u Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, Kansas, USA
700    1_
$a Michaud, Gregory F $u Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA
700    1_
$a Dukkipati, Srinivas R $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Cammack, Sam $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: vivek.reddy@mountsinai.org
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 7, č. 1 (2021), s. 109-123
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33478702 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133042 $b ABA008
999    __
$a ok $b bmc $g 1715097 $s 1146782
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 7 $c 1 $d 109-123 $e 20201028 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options